Kymera Therapeutics KYMR Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

Johnson & JohnsonJNJ

25.7%-4.5pp

Regeneron PharmaceuticalsREGN

14%-1.3pp

Nurix Therapeutics, Inc.NRIX

-80.3%+113pp

ArvinasARVN

-42.3%-53.5pp

Monte Rosa Therapeutics, Inc.GLUE

-42.7%—

FAQ

What is Kymera Therapeutics's return on equity?

Kymera Therapeutics (KYMR) reported return on equity of -24.2% in Q2 2026.

How has Kymera Therapeutics's return on equity changed year-over-year?

Kymera Therapeutics's return on equity increased by 27.4% year-over-year, from -33.3% to -24.2%.

What is the long-term trend for Kymera Therapeutics's return on equity?

Over 4 years (2021 to 2025), Kymera Therapeutics's return on equity has grown at a -1.1% compound annual growth rate (CAGR), from -27% to -25.8%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.